Nirmatrelvir-Ritonavir Fails to Improve Long-COVID
By Peter A. McCullough, MD, MPH Paxlovid, the Pfizer drug combination of nirmatrelvir and ritonavir is a dual action antiviral agent that had mixed results in acute COVID-19 and a CDC Health Advisory slapped on it for prolonging the COVID-19 illness with rebound. Long-COVID is caused by accumulation of vaccine and SARS-CoV-2 Spike protein in […]
Discuss on Nostr!
Nostr Note ID note1z9yt9h2h5nlu0p2f85n79g2whypwvz3djqndawx0xnk0n8gds7mqn2uxzm Open on Primal.net Open on Snort.social Open on Iris.to Open on Coracle.social
New to Nostr?
Create an account now & join the conversation!
Promote it on DissentWatch!
- To advertise this post for $0.02 per visit send bitcoins to the address below
- The post will be promoted daily via social media & our "Featured News" display in multiple places
- You can add more anytime
- Ranking order in the Featured News box is based on the balance remaining
Received: 0 mBTC (0.00 USD)
Spent: 0 mBTC (0.00 USD)
Balance: 0 mBTC (0.00 USD)
The amounts above may be lagging behind. If you just sent a payment click below to get more up to date results and push the post to the "Featured News" box faster.